“Amgen’s takeaway is simple yet profound: The current system is working, and innovation is benefiting actual patients.”
The ongoing policy debate about pharmaceutical and biologic patents has been coopted by those who don’t like patents—including those who have a financial incentive not to like patents. These paid mercenaries concoct and then disseminate fraudulent “reports”, which have become the lifeblood for patent critics. Even when the inaccuracies and lies are clearly identified, the cacophony of patent haters drowns out the truth thanks to a complicit, ideologically aligned popular press that continues to cite and rely on fabricated “findings” that couldn’t stand up to the scrutiny of your average fifth grader.
Although not the only example by a longshot, the easiest, most clear example of fiction masquerading as truth comes to us courtesy of the Initiative for Medicines, Access & Knowledge (I-MAK), which the Council for Innovation Promotion (C4IP) has recently launched a campaign to expose. As recently as July 2023, I-MAK’s website proclaimed there was “no generic alternative to Pfizer’s drug Lyrica approved by the Food and Drug Administration (FDA) or available on the market.”
I-MAK’s claim about Lyrica is false. The FDA approved multiple generics of Lyrica in July 2019, which coincided with the patent expiration of the Lyrica compound patent in June 2019. And those generics were on the market well before I-MAK made this incorrect...
Victoria’s Essential Services Commission (ESC), the state’s main regulator, says it has suspended another business from the Victorian Energy Upgrades (VEU) program after alleged false claims. The ...